Determinants of Influenza Non-Vaccination Among Canadian Children: Insights from a Nationwide Survey A Alami, S Dave, C Uhlik, M Ebrahim, D Krewski, J Laroche Frontiers in Public Health 12, 1400782, 2024 | | 2024 |
Safety of RSV Vaccine among Pregnant Individuals: A Real-World Pharmacovigilance Study Using Vaccine Adverse Event Reporting System A Alami, S Perez-Lloret, D Mattison medRxiv, 2024.04. 19.24306090, 2024 | 1 | 2024 |
Myocarditis and pericarditis post-mRNA COVID-19 vaccination: insights from a pharmacovigilance perspective A Alami, PJ Villeneuve, PJ Farrell, D Mattison, N Farhat, N Haddad, ... Journal of Clinical Medicine 12 (15), 4971, 2023 | 4 | 2023 |
Interventions for COVID-19 vaccine hesitancy: a systematic review and narrative synthesis R Terrell, A Alami, D Krewski International Journal of Environmental Research and Public Health 20 (12), 6082, 2023 | 6 | 2023 |
Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis A Alami, D Krewski, N Farhat, D Mattison, K Wilson, CA Gravel, PJ Farrell, ... BMJ open 13 (6), e065687, 2023 | 19 | 2023 |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the … M Otero-Losada, N Petrovsky, A Alami, JA Crispo, D Mattison, F Capani, ... Expert Opinion on Drug Safety 22 (4), 343-349, 2023 | 10 | 2023 |
Safety and effectiveness of n-methyl-d-aspartate (NMDA) receptor antagonists for depression: A narrative review GC Alexander, TJ Moore, A Alami, D Mattison PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 588-589, 2022 | | 2022 |
Safety and effectiveness of NMDA receptor antagonists for depression: a multidisciplinary review TJ Moore, A Alami, GC Alexander, DR Mattison Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42 (7 …, 2022 | 20 | 2022 |
Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations A Alami, D Krewski, D Mattison, K Wilson, CA Gravel, PJ Villeneuve, ... Vaccines 10 (5), 722, 2022 | 15 | 2022 |
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system MK Taher, A Alami, CA Gravel, D Tsui, LM Bjerre, F Momoli, D Mattison, ... Expert opinion on drug safety 21 (2), 269-276, 2022 | 7 | 2022 |
The mysterious beauty of ketamine: Benefits and risks DR Mattison, A Alami, TJ Moore, GC Alexander Advances in Neurotoxicology 8, 179-185, 2022 | | 2022 |
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the … S Perez-Lloret, N Petrovsky, A Alami, JAG Crispo, D Mattison, ... medRxiv, 2021.09. 28.21264245, 2021 | 4 | 2021 |
Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system MK Taher, A Alami, CA Gravel, D Tsui, LM Bjerre, F Momoli, DR Mattison, ... JGH Open 5 (7), 778-784, 2021 | 3 | 2021 |